TCT 2018 | MAIN COMPARE: Angioplasty vs. Surgery for Left Main Coronary Artery Disease at 10 Years

Several studies (some of them recent, some of them not so much so) have compared left main coronary artery angioplasty and myocardial revascularization surgery. Combined, these works compose a large corpus of evidence, but follow-up has not gone beyond 5 years in any case. The main aim of this study (presented at TCT 2018 and published simultaneously in JACC) was to achieve a 10-year follow-up (median: 12 years).

TCT 2018 | MAIN COMPARE: Angioplastia vs cirugía para el tronco a 10 añosThe MAIN COMPARE registry included 2240 patients with LMCA lesions (1102 who underwent angioplasty and 1138 who underwent surgery) between 2000 and 2006. Among all angioplasty patients, about 318 received conventional stents.

 

The primary endpoint was a composite of death, infarction, stroke, and target-vessel revascularization. Different statistical tools were used for population comparison.

 

In the overall cohort, there was no significant difference as regards death, infarction, or stroke, but there were differences regarding revascularization, particularly taking into account that around 30% of patients received conventional stents.


Read also: TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation.


As regards the cohort of patients who received drug-eluting stents (DES), there was no difference in the combined endpoint at 5 years, even though, beyond that period, patients who underwent angioplasty were at a higher risk of death and combined events than those who underwent surgery. Such a difference disappeared once populations were compared after propensity score matching, as it had been previously specified.

 

Original title: Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Presenter: Seung-Jung Park.

 

MAIN-COMPARE-presentación

MAIN-COMPARE-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...